OKYO Pharma (OKYO) vs Verrica Pharmaceuticals (VRCA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Verrica Pharmaceuticals (VRCA) has outperformed OKYO Pharma (OKYO) over the past year, losing 5.4% versus a loss of 37.9%. OKYO Pharma is the larger company by market cap ($72.9 million vs $71.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OKYO | VRCA |
|---|---|---|
| Share price | $1.39 | $4.18 |
| Market cap | $72.95M | $71.81M |
| 1-day change | -2.73% | +0.97% |
| YTD return | -32.85% | -49.70% |
| 1-year return | -37.95% | -5.43% |
| 5-year return | — | -96.87% |
| EPS (TTM) | $-0.24 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $9.82 |
| 52-week low | $1.27 | $3.28 |
| Distance from 52-week high | -56.56% | -57.44% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +499.28% | +230.86% |
| Average volume | 94.59K | 62.56K |
| Shares outstanding | 52.48M | 17.18M |
| Employees | 5 | 76 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VRCA has outperformed OKYO by 32.5 percentage points over the past year.
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
About Verrica Pharmaceuticals
VRCA stock →Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.
Healthcare · Biotechnology · 76 employees
OKYO vs VRCA FAQ
Which is bigger, OKYO Pharma or Verrica Pharmaceuticals?
OKYO Pharma (OKYO) is larger, with a market capitalization of $72.95M compared with $71.81M for Verrica Pharmaceuticals (VRCA).
Which stock has performed better over the past year, OKYO or VRCA?
VRCA returned -5.43% over the past 12 months, compared with -37.95% for OKYO (price return, excluding dividends). Past performance does not predict future results.
Are OKYO Pharma and Verrica Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.